BACKGROUND: We hypothesized that atorvastatin combined with amlodipine has additive
beneficial vascular and metabolic effects that are superior to monotherapy in patients with …

Background—Biological mechanisms underlying statin and angiotensin II type 1 receptor
blocker therapies differ. Therefore, we compared vascular and metabolic responses to these …

Background: In many countries, combination therapy with amlodipine and atorvastatin is
indicated for the treatment of patients with hypertension and hypercholesterolemia. The aim …

Guidelines stress the importance of the simultaneous management of multiple
cardiovascular risk factors. This can in part be achieved by coadministration of lipid …

BACKGROUND: Reciprocal relationships between endothelial dysfunction and insulin
resistance imply that improvement in endothelial dysfunction will have beneficial metabolic …

Hypertension (HTN) and dyslipidemia (DYS) commonly coexist. Patients with concurrent
HTN and DYS are at high risk of cardiovascular disease, yet most patients do not achieve …

The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of
coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia …

The plasma level of adiponectin, which is known as an anti-atherogenic adipocytokine,
correlates inversely with the progression of atherosclerosis. An increase in the serum …

BACKGROUND Current treatment for the secondary prevention of cardiovascular diseases
frequently involves the prescription of several combination therapies, particularly …

BACKGROUND: ASCOT-BPLA study demonstrates that in hypertensive subjects, atenolol+
bendroflumethiazide therapy is associated with higher incidence of adverse cardiovascular …